COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,507 Articles (22,870 medRxiv, 8,637 bioRxiv)

Most recent first Previous |  Page 1014: Articles 10131-10140  | Next

Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response
Dehgani-Mobaraki, P., Wang, C., Floridi, A., Floridi, E., Zaidi, A. K.
10.1101/2022.01.18.22269349 — Posted: 2022-01-20
SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice
Lee, K. S., Wong, T. Y., Russ, B. P., Horspool, A. M., Miller, O., Rader, N., Givi, J. P., Winters, M. T., Wong, Z. Y., Cyphert, H. A., Denvir, J., Stoilov, P. G., Barbier, M., Roan, N., Amin, M. S., Martinez, I., Bevere, J. R., Damron, F. H.
10.1101/2022.01.18.476863 — Posted: 2022-01-19
Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals
Lapa, D., Grousova, D., Matusali, G., Meschi, S., Colavita, F., Bettini, A., Gramigna, G., Francalancia, M., Garbuglia, A. R., Girardi, E., Puro, V., Antinori, A., Kovyrshina, A., Dolzhikova, I., Shcheblyakov, D., Tukhvatulin, A., Zubkova, O., Logunov, D., Naroditsky, B., Vaia, F., Gintsburg, A.
10.1101/2022.01.15.22269335 — Posted: 2022-01-19 Discussion: Onsite
Loss of Y in leukocytes as a risk factor for critical COVID-19 in men
Bruhn-Olszewska, B., Davies, H., Sarkisyan, D., Juhas, U., Rychlicka-Buniowska, E., Wojcik, M., Horbacz, M., Jakalski, M., Olszewski, P., Westholm, J. O., Smialowska, A., Wierzba, K., Torinsson Naluai, A., Jern, N., Andersson, L.-M., Jarhult, J., Filipowicz, N., Tiensuu Janson, E., Rubertsson, S., Lipcsey, M., Gisslen, M., Hultstrom, M., Frithiof, R., Dumanski, J. P.
10.1101/2022.01.19.22269521 — Posted: 2022-01-19
High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses
Sims, J. J., Lian, S., Wilson, J. M.
10.1101/2022.01.17.476672 — Posted: 2022-01-19
Differences in environmental stability among SARS-CoV-2 variants of concern: Omicron has higher stability
Hirose, R., Itoh, Y., Ikegaya, H., Miyazaki, H., Watanabe, N., Yoshida, T., Bandou, R., Daidoji, T., Nakaya, T.
10.1101/2022.01.18.476607 — Posted: 2022-01-19 Discussion: Onsite
Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant
Rosales, R., McGovern, B. L., Rodriquez, M. L., Rai, D. K., Cardin, R. D., Anderson, A. S., Sordillo, E. M., van Bakel, H., Simon, V., Garcia-Sastre, A., White, K. M.
10.1101/2022.01.17.476685 — Posted: 2022-01-19
Prediction and validation of host cleavage targets of SARS-CoV-2 3C like protease
Yucel, N., Marchiano, S., Tchelepi, E., McAfee, Q., Nimmagadda, N., Ren, A., Shi, S., Murry, C. E., Arany, Z.
10.1101/2022.01.17.476677 — Posted: 2022-01-19
Cross-sectional study to assess the efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies
Abella, E., Trigueros, M., Pradenas, E., Munoz Lopez, F., Garcia Pallarols, F., Ben Azaiz Ben Lahsen, R., Trinite, B., Urrea, V., Marfil, S., Rovirosa, C., Puig, T., Grau, E., Chamorro, A., Toledo, R., Font, M., Palacin, D., Lopez Segui, F., Carrillo, J., Prat, N., Mateu, L., Clotet, B., Blanco, J., Massanella, M.
10.1101/2022.01.19.22269531 — Posted: 2022-01-19
Serum extracellular vesicles trace COVID-19 progression and immune responses
Yim, K. H. W., Borgoni, S., Chahwan, R.
10.1101/2022.01.19.22269529 — Posted: 2022-01-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).